Evolution of HVR-1 quasispecies after 1-year treatment in HIV/HCV-coinfected patients according to the pattern of response to highly active antiretroviral therapy

Antiviral Therapy

Volumn 11, Issue 1, 2006, Pages 87-94

  Solmone, Mariacarmela ^a   Girardi, Enrico ^a   Lalle, Eleonora ^a   Abbate, Isabella ^a   Monforte, Antonella D'Arminio ^b   Cozzi Lepri, Alessandro ^c   Alessandrini, Anna ^d   Piscopo, Rita ^e   Ebo, Francesca ^f   Cosco, Lucio ^g   Antonucci, Giorgio ^a   Ippolito, Giuseppe ^a   Capobianchi, Maria R ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d UNIVERSITY OF GENOA   (Italy)

^e GALLIERA HOSPITAL   (Italy)

^f Hosp Civile San Giovanni e Paolo   (Italy)

^g A Pugliesi Catanzaro ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; GLYCOPROTEIN E2; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MALE; PHYLOGENY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; EVOLUTION, MOLECULAR; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV; HIV INFECTIONS; HUMANS; MALE; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; VIRAL PROTEINS;

EID: 33644544743     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Rockstroh JK & Spengler U. HIV and hepatitis C virus co-infection Lancet Infect Dis 2004; 4:437-444.
2. Soto B, Sanchez-Quijano A, Rodrigo L, del Olmo JA, Garcia Bengoechea M, Hernandez-Quero J, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol. 1997; 26:1-5.
3. Benhamou Y, Di Martino V, Bochet M, Colombet G, Thibault V, Liou A, et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-patients: impact of protease inhibitor therapy. Hepatology 2001; 34:283-287.
4. Garcia-Samaniego J, Soriano V, Castilla J, Bravo R, Moreno A, Carbo J, et al. Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. The Hepatitis/HIV Spanish Study Group. Am J Gastroenterol 1997; 92:1130-1134.
5. Qurishi N, Kreuzberg C, Luchters G, Effenberger W, Kupfer B, Sauerbruch T, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus co-infection. Lancet 2003; 362:1708-1713.
6. Cribier B, Rey D, Schmitt C, Lang JM, Kirn A & Stoll-Keller F. High hepatitis C viraemia and impaired antibody response in patients with HIV. AIDS 1995; 9:1131-1136.
7. Di Martino V, Rufat P, Boyer N, Renard P, Degos F, Martinot-Peignoux M, et al. The influence of human immunodeficiency virus co-infection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 2001; 34:1193-1199.
8. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus co-infection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800-1805.
9. Erratum in: Lancet 2001; 357:1536.
10. De Luca A, Bugarini R, Lepri AC, Puoti M, Girardi E, Antinori A, et al. Italian Cohort Naive Antiretrovirals Study Group. Co-infection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med 2002; 162:2125-2132.
11. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE & Thomas DL. Hepatitis C and progression of HIV disease. JAMA 2002; 288:199-206.
12. Rockstroh J, Konopnicki D, Soriano V, Kirk O, Antunes F, Knysz B, et al. Hepatitis B and hepatitis C in the EuroSIDA cohort: prevalence and effect on mortality, AIDS, progression and response to HAART. 11th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2004, San Francisco, USA. Abstract 799.
13. Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 2003; 163:2187-2195.
14. Antonucci G, Cozzi-Lepri A, Girardi E, Capobianchi MR, De Luca A, d'Arminio Monforte A, et al. Effect of hepatitis C virus genotype on CD4+ T cell count in a cohort of antiretroviral-naive HIV-1-infected individuals. J Infect Dis 2005; 192:703-704.
15. Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, et al. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. Clin Infect Dis. 2005; 40:101-109.
16. Goodenow M, Huet T, Saurin W, Kwok S, Sninsky J & Wain-Hobson S. HIV-1 isolates are rapidly evolving quasispecies: evidence for viral mixtures and preferred nucleotide substitutions. J Acquir Immune Defic Syndr 1989; 2:344-352.
17. Oshima M, Tsuchiya M, Yagasaki M, Orita T, Hasegawa M, Tomonoh K, et al. cDNA clones of Japanese hepatitis C virus genomes derived from a single patient show sequence heterogeneity. J Gen Virol 1991; 72:2805-2809.
18. Martell M, Esteban JI, Quer J, Genesca J, Weiner A, Esteban R, et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 1999; 66:3225-3229.
19. Kato N, Ootsuyama Y, Sekiya H, Ohkoshi S, Nakazawa T, Hijikata M, et al. Genetic drift in hypervariable region 1 of the viral genome in persistent hepatitis C virus infection. J Virol 1994; 68:4776-4784.
20. Kurosaki M, Enomoto N, Marumo F & Sato C. Rapid sequence variation of the hypervariable region of hepatitis C virus during the course of chronic infection. Hepatology 1993; 18:1293-1299.
21. Weiner AJ, Geysen HM, Christopherson C, Hall JE, Mason TJ, Saracco G, et al. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci USA 1992; 89:3468-3472.
22. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288:339-344.
23. Kumar U, Monjardino J & Thomas HC. Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient. Gastroenterology 1994; 106:1072-1075.
24. Lawal Z, Petrik J, Wong VS, Alexander GJ & Allain JP. Hepatitis C virus genomic variability in untreated and immunosuppressed patients. Virology 1997; 228:107-111.
25. Abbate I, Lo Iacono O, Di Stefano R, Cappiello G, Girardi E, Longo R, et al. HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin. J Hepatol 2004; 40:831-836.
26. Enomoto N, Kurosaki M, Tanaka Y, Marumo F & Sato C. Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism analysis. J Gen Virol 1994; 75:1361-1369.
27. Blackard JT, Yang Y, Bordoni P, Sherman KE, Chung RT & AIDS Clinical Trials Group 383 Study Team. Hepatitis C virus (HCV) diversity in HIV-HCV- subjects initiating highly active antiretroviral therapy. J Infect Dis 2004; 189:1472-1481.
28. Dove LM, Phung Y, Wrock J, Kim M & Wright TL. Abstract. Hepatology 1999; 30:456.
29. Mao Q, Ray SC, Laeyendecker O, Ticehurst JR, Strathdee SA, Vlahov D, et al. Human immunodeficiency virus seroconversion and evolution of the hepatitis C virus quasispecies. J Virol 2001; 75:3259-3267.
30. Roque-Afonso AM, Robain M, Simoneau D, Rodriguez-Mathieu P, Gigou M, Meyer L, et al. Influence of CD4 cell counts on the genetic heterogeneity of hepatitis C virus in patients with human immunodeficiency virus. J Infect Dis 2002; 185:728-733.
31. Toyoda H, Fukuda Y, Koyama Y, Takamatsu J, Saito H & Hayakawa T. Effect of immunosuppression on composition of quasispecies population of hepatitis C virus in patients with chronic hepatitis C with human immunodeficiency virus. J Hepatol 1997; 26:975-982.
32. Babik JM & Holodniy M. Impact of highly active antiretroviral therapy and immunologic status on hepatitis C virus quasispecies diversity in human immunodeficiency virus/hepatitis C virus- patients. J Virol 2003; 77:1940-1950.
33. Sherman KE, Shire NJ, Cernohous P, Rouster SD, Omachi JH & Brun S. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir. Clin Infect Dis 2005; 41:1186-1195.
34. Mijch A, Sasadeusz J, Hellard M, Dunne M, McCaw R Bowden S, et al. A study to investigate the impact of the initiation of highly active antiretroviral therapy on the hepatitis C virus viral load in HIV/HCV-coinfected patients. Antivir Ther 2005; 10:277-284.
35. Chung RT, Evans SR, Yang Y, Theodore D, Valdez H, Clark R, et al. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in coinfected subjects. AIDS 2002; 16:1915-1923.
36. Caudai C, Pianese M, Zacchini F, Toti M, Zazzi M & Valensin PE. Longitudinal study in HIV/HCV-coinfected HAART-naive patients and role of HCV genotype. J Clin Virol 2005; 32:151-155.